NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News

$55.50

+2.40 (+4.52%)

(As of 09/26/2023 ET)

Compare

Today's Range: $52.43
▼
$55.52
50-Day Range: $50.00
▼
$61.26
52-Week Range: $6.93
▼
$63.40

Volume: 298,186 shs
Average Volume: 457,753 shs
Market Capitalization: $3.47 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $58.80

MoonLake Immunotherapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 5.9% Upside
$58.80 Price Target
Short Interest: Healthy
16.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.45
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$40 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.93) to ($1.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

825th out of 964 stocks

Biotechnology Industry

23rd out of 29 stocks

2.4

Analyst's Opinion

Consensus Rating
MoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $58.80, MoonLake Immunotherapeutics has a forecasted upside of 5.9% from its current price of $55.50.
Amount of Analyst Coverage
MoonLake Immunotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
16.84% of the float of MoonLake Immunotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in MoonLake Immunotherapeutics has recently decreased by 10.12%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MoonLake Immunotherapeutics does not currently pay a dividend.
Dividend Growth
MoonLake Immunotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MLTX.

3.0

News and Social Media Coverage

News Sentiment
MoonLake Immunotherapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for MoonLake Immunotherapeutics this week, compared to 2 articles on an average week.
Search Interest
14 people have searched for MLTX on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.
MarketBeat Follows
5 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MoonLake Immunotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,000,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
15.27% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($0.93) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MoonLake Immunotherapeutics is -53.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MoonLake Immunotherapeutics is -53.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MoonLake Immunotherapeutics has a P/B Ratio of 42.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

MLTX Price History

30 days | 90 days | 365 days | Advanced Chart

MLTX Stock News Headlines

September 25, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Moderate Buy" by Brokerages

September 19, 2023 | americanbankingnews.com

Cantor Fitzgerald Reiterates "Overweight" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

September 27, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 18, 2023 | finance.yahoo.com

These 8 Stocks Are Outperforming Nvidia In 2023

September 17, 2023 | msn.com

Acelyrin, MoonLake rivalry heats up as both chase blockbuster PsA market

September 17, 2023 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Downgraded to "Neutral" at Bryan, Garnier & Co

September 15, 2023 | msn.com

Cantor Fitzgerald Reiterates MoonLake Immunotherapeutics - (MLTX) Overweight Recommendation

September 14, 2023 | wsj.com

MoonLake Immunotherapeutics

September 27, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 13, 2023 | msn.com

Needham Reiterates MoonLake Immunotherapeutics - (MLTX) Buy Recommendation

September 12, 2023 | finance.yahoo.com

The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10%

September 12, 2023 | fool.com

Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday

September 12, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), InflaRx (IFRX)

September 6, 2023 | finance.yahoo.com

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

August 31, 2023 | msn.com

Needham Initiates Coverage of MoonLake Immunotherapeutics - (MLTX) with Buy Recommendation

August 28, 2023 | msn.com

Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)

August 14, 2023 | msn.com

Wedbush Reiterates MoonLake Immunotherapeutics - (MLTX) Outperform Recommendation

August 13, 2023 | fool.com

MoonLake Immunotherapeutics (NASDAQ: MLTX)

August 11, 2023 | markets.businessinsider.com

Jefferies Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

August 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Ligand Pharma (LGND) and Immunocore Holdings (IMCR)

August 11, 2023 | markets.businessinsider.com

MoonLake Immunotherapeutics (MLTX) Receives a Buy from LifeSci Capital

August 10, 2023 | finanznachrichten.de

MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 10, 2023 | finance.yahoo.com

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 2, 2023 | msn.com

MoonLake Immunotherapeutics - (MLTX) Price Target Increased by 11.60% to 61.81

August 1, 2023 | msn.com

Wedbush Maintains MoonLake Immunotherapeutics - (MLTX) Outperform Recommendation

July 28, 2023 | markets.businessinsider.com

Wedbush Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

July 25, 2023 | finance.yahoo.com

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

See More Headlines

Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLTX Company Calendar

Last Earnings: 8/10/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MLTX
CUSIP: N/A
CIK: 1821586
Web: www.moonlaketx.com
Phone: 41-41-510-8022
Fax: N/A
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $58.80
High Stock Price Forecast: $86.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +5.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -23.18%
Return on Assets: -22.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 70.97
Quick Ratio: 70.97

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: 42.69

Miscellaneous

Outstanding Shares: 62,446,000
Free Float: 52,910,000
Market Cap: $3.47 billion
Optionable: Not Optionable
Beta: 1.46

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Jorge Santos da Silva (Age 45)
Co-Founder, CEO & Director
Comp: $1.11M

Dr. Kristian Reich (Age 57)
Co-Founder & Chief Scientific Officer
Comp: $1.2M

Mr. Matthias Bodenstedt (Age 35)
Chief Financial Officer
Comp: $588.25k

Mr. Oliver Daltrop
Chief Technical Officer

Nicolas Mosimann
Gen. Counsel

Annett Zippel
Director of People & Culture

Ms. Nuala Brennan
Chief Clinical Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MLTX Stock - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings or view top-rated stocks.
What is MoonLake Immunotherapeutics' stock price forecast for 2023?: 10 Wall Street research analysts have issued 1 year target prices for MoonLake Immunotherapeutics' shares. Their MLTX share price forecasts range from $16.00 to $86.00. On average, they predict the company's stock price to reach $58.80 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts.
How have MLTX shares performed in 2023?: MoonLake Immunotherapeutics' stock was trading at $10.50 at the start of the year. Since then, MLTX stock has increased by 428.6% and is now trading at $55.50.
View the best growth stocks for 2023 here.
When is MoonLake Immunotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our MLTX earnings forecast.
How were MoonLake Immunotherapeutics' earnings last quarter?: MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04.
What ETFs hold MoonLake Immunotherapeutics' stock?: ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA SmallCap Momentum ETF (DWAS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Harbor Health Care ETF (MEDI), First Trust IPOX Europe Equity Opportunities ETF (FPXE) and BlackRock Future Health ETF (BMED).Goldman Sachs Future Health Care Equity ETF (GDOC).

What is MoonLake Immunotherapeutics' stock symbol?: MoonLake Immunotherapeutics trades on the NASDAQ under the ticker symbol "MLTX."
Who are MoonLake Immunotherapeutics' major shareholders?: MoonLake Immunotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (15.45%), Citadel Advisors LLC (3.83%), Alliancebernstein L.P. (1.59%), Polar Capital Holdings Plc (1.40%), BlackRock Inc. (1.25%) and Banque Pictet & Cie SA (1.21%).
View institutional ownership trends.
How do I buy shares of MoonLake Immunotherapeutics?: Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MoonLake Immunotherapeutics' stock price today?: One share of MLTX stock can currently be purchased for approximately $55.50.
How much money does MoonLake Immunotherapeutics make?: MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $3.47 billion. The company earns $-49,970,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.
How can I contact MoonLake Immunotherapeutics?: The official website for the company is www.moonlaketx.com. The company can be reached via phone at 41-41-510-8022 or via email at ir@moonlaketx.com.

This page (NASDAQ:MLTX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News

MoonLake Immunotherapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

MLTX Price History

MLTX Stock News Headlines

MLTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MLTX Stock - Frequently Asked Questions

Overall MarketRank^™